Le Lézard
Classified in: Health
Subject: ATY

Moore Kuehn, PLLC Encourages Genomic Health, Inc. and Carbonite, Inc. Investors to Contact Firm


NEW YORK, Oct. 17, 2019 /PRNewswire/ -- Moore Kuehn, PLLC, a securities law firm located on Wall Street in downtown New York City, is investigating potential claims involving the directors and officers regarding possible breaches of fiduciary duties and other violations of law related to merger agreements, inaccurate developments and/or financial projections.

(PRNewsfoto/Moore Kuehn, PLLC)

Genomic Health, Inc. (NASDAQ: GHDX)

Genomic Health, Inc. may merge with Exact Sciences Corp. (NASDAQ: EXAS). Moore Kuehn is investigating Genomic Health's board of directors' decision to sell the company now rather than allow shareholders to continue to participate in the company's continued success and future growth prospects.

Carbonite, Inc.  (NASDAQ: CARB)

Before July 25, 2019, the officers and directors of Carbonite issued positive projections and financial forecasts despite having information to the contrary.

Specifically, the officers and directors failed to disclose that: (i) Carbonite's Server Backup VM Edition was of poor quality and technologically flawed; (ii) Carbonite was receiving poor reviews and complaints from customers about the Server Backup VM Edition; and (iii) the poor quality and technological flaws of the Server Backup VM Edition were acting as a "disruptive" factor throughout the Carbonite salesforce and keeping that sales organization from closing opportunistically on several larger deals during fiscal 2019; and (iv) as a result of the foregoing, Carbonite lacked any reasonable basis for issuing its positive projections and financial forecasts.

On July 25, 2019, Carbonite, conceded that it was withdrawing the Server Backup VM Edition from the marketplace and consequently dramatically lowered its financial projections for fiscal 2019 and 2020. On the same day, Carbonite's Chief Executive Officer announced he was leaving the Company.

Moore Kuehn encourages shareholders to contact Fletcher Moore, Esq. by email at [email protected] or telephone at (212) 709-8245. There is no cost or obligation to you.

Moore Kuehn is a New York-based law firm with attorneys representing investors and consumers in class action litigation involving securities law violations, financial fraud, breaches of fiduciary duties, and other claims. For additional information about Moore Kuehn, please go to http://www.moorekuehn.com/practice/new-york-securities-litigation/.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts:
Moore Kuehn, PLLC
Fletcher Moore, Esq.
30 Wall Street, 8th Floor
New York, New York 10005
[email protected]
(212) 709-8245

SOURCE Moore Kuehn, PLLC


These press releases may also interest you

at 13:26
In a bid to foster excellence and innovation in the healthcare industry, the esteemed Dr. Vidal Sheen proudly announces the launch of The Dr. Vidal Sheen Grant for Healthcare Students. With a robust focus on academic prowess, compassionate care, and...

at 13:17
Rexall is proud to unveil its first Pharmacist Care Walk-In Clinic in Barrie, Ontario on Friday, April 19. Located at 353 Duckworth Street, the clinic will offer personalized care to the community while providing immediate pharmacist treatment for...

at 13:13
Caring for communities extends beyond life-changing work in operating rooms and physician offices. Hartford HealthCare leadership today highlighted its corporate responsibility to environmental, social and economic sustainability in announcing its...

at 13:04
Concept Medical, a pioneer in innovative drug delivery technologies, proudly announces the commencement of its groundbreaking IDE clinical study, "MAGICAL-ISR" using MagicTouch ? Sirolimus drug coated balloon (DCB), for the management of in-stent...

at 12:30
The American College of Physicians (ACP) today released an update of its 2017 guideline with clinical recommendations for the use of newer pharmacological treatments of adults with Type 2 diabetes. The clinical guideline is based on the best...

at 12:10
Pieris Pharmaceuticals, Inc. today announced that its Board of Directors has approved a 1-for-80 reverse stock split of the Company's common stock, par value $0.001, which will be effective at 5:00 pm Eastern Time on April 22, 2024. The Company's...



News published on and distributed by: